Plakous lands $1.7m from NIH to develop newborn treatment

Plakous Therapeutics announced that it received more than $1.7 million in a research grant from he Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health (NIH).

The Phase I-II fast-track small business innovation research (SBIR) grant, worth up to $1.725 million, is slated to help Plakous develop novel therapies for preventing the necrotizing enterocolitis (NEC) disease in premature babies. The grant is set to supplement Plakous’ currently open $4 million seed round.

Get the full story at our sister site, Drug Discovery & Development.

Read more
  • 0

Plakous lands $1.7m from NIH to develop newborn treatment

Plakous Therapeutics announced that it received more than $1.7 million in a research grant from he Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health (NIH).

The Phase I-II fast-track small business innovation research (SBIR) grant, worth up to $1.725 million, is slated to help Plakous develop novel therapies for preventing the necrotizing enterocolitis (NEC) disease in premature babies. The grant is set to supplement Plakous’ currently open $4 million seed round.

Winston-Salem, N.C.-based Plakous develops the Protego-PD system to prevent NEC by accelerating intestinal maturation of premature infants. Protego-PD is an orally delivered acellular biotherapeutic developed from post-delivery placentas.

The company’s chief scientific officer Seth Tomblyn will be the principal investigator for the three-year project funded by the grant, according to a news release.

“This …

Read more
  • 0